Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 4:19:29-48.
doi: 10.2147/PPA.S502645. eCollection 2025.

A Systematic Review Uncovering Modifiable Influences on Statin Adherence

Javiera Rosenberg  1 , Smaragda Lampridou  1   2 , Amelia Moores  1 , Sara Garfield  3 , David Wingfield  1   4 , Gaby Judah  1
Affiliations
Review

A Systematic Review Uncovering Modifiable Influences on Statin Adherence

Javiera Rosenberg et al. Patient Prefer Adherence. .

Abstract

Statins are effective in reducing cardiovascular disease (CVD) risk, but adherence rates remain low globally. Understanding and addressing modifiable influences on adherence is key to improving outcomes. Existing reviews have methodological limitations, often failing to integrate qualitative and quantitative data or consider specific barriers to statin adherence. This systematic review aimed to identify modifiable barriers and facilitators to statin adherence using the Theoretical Domains Framework (TDF). A comprehensive search of Embase, MEDLINE, PsycINFO, and CINAHL was conducted, covering studies from January 1998 to November 2023. Data were coded to TDF domains and synthesized to identify specific influences on adherence. The nature of the evidence (qualitative or quantitative) was recorded for each influence, and variations among patient groups were noted. Seventy studies from 20 countries were included, with only one focused on ethnic minorities. The most commonly identified domains affecting adherence were "Beliefs about Consequences", "Knowledge", 'Environmental Context and Resources', and "Social Influences". Key factors included knowledge of disease, perceived disease threat, perceived benefits of statins, and patient-provider communication and trust. While side effects had inconsistent associations with adherence, forgetfulness was mainly addressed in quantitative studies, and social influences were highlighted in qualitative research. This review identified modifiable factors that could improve statin adherence. Future research should focus on addressing barriers faced by underrepresented groups to create more inclusive and effective interventions that enhance patient support and communication for better health outcomes.

Keywords: dyslipidaemia; medication adherence; psychological determinants; theoretical domains framework.

Plain language summary

People are prescribed statins to prevent strokes and heart attacks. This study combines findings from previous studies to understand why many people do not take statins as prescribed. Common barriers to taking statins included not thinking being at risk of strokes and heart attacks, believing statins are harmful, experiencing side effects and poor communication and trust with healthcare professionals. Common things encouraging statin taking included thinking statins have benefits, having cholesterol levels checked, routines and methods to remember statin intake and having ways of dealing with side effects.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

None
Graphical abstract
Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Diagram.
See this image and copyright information in PMC

References

    1. World Heart Federation. World heart report 2023: confronting the world’s number one killer. 2023.
    1. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol. 2010;35(2):72–115. doi:10.1016/j.cpcardiol.2009.10.002 - DOI - PMC - PubMed
    1. Treatment Trialists C C, Fulcher J, R O, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–1405. doi:10.1016/S0140-6736(14)61368-4 - DOI - PubMed
    1. Ofori-Asenso R, Jakhu A, Zomer E, et al. Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis. J Gerontol a Biol Sci Med Sci. 2018;73(6):813–819. doi:10.1093/gerona/glx169 - DOI - PubMed
    1. Danese MD, Gleeson M, Kutikova L, et al. Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open. 2017;7(5):e013851. doi:10.1136/bmjopen-2016-013851 - DOI - PMC - PubMed

LinkOut - more resources